Literature DB >> 4022501

Conservative treatment of borderline ovarian tumors.

H D Tazelaar, D G Bostwick, S C Ballon, M R Hendrickson, R L Kempson.   

Abstract

Of 61 patients with stage IA borderline ovarian tumors, 41 were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy, and 20 were treated by a variety of more limited operations, including cystectomy with (one patient) and without (three patients) a contralateral ovarian wedge biopsy, and unilateral salpingo-oophorectomy with (six patients) and without (ten patients) a contralateral wedge biopsy. In the group treated conservatively, there were 11 serous, seven mucinous, and two mixed seromucinous borderline tumors, whereas in the total abdominal hysterectomy and bilateral salpingo-oophorectomy treatment group there were 26 serious, 12 mucinous, and three mixed seromucinous borderline tumors. After a mean follow-up of 89 months (range 36 to 244 months), subsequent borderline neoplasms had developed in three patients (15%) with serious borderline tumors initially treated conservatively and in two patients (5%) with serous or mixed seromucinous borderline tumors initially treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy. No patient with a mucinous borderline tumor treated either conservatively or with total abdominal hysterectomy and bilateral salpingo-oophorectomy developed a subsequent neoplasm. All 61 patients in the study group are alive and free of disease, including those who developed recurrent neoplasm.

Entities:  

Mesh:

Year:  1985        PMID: 4022501

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  [Long-term follow-up of patients with borderline tumors of the ovaries].

Authors:  R Adam; D Thyselius; M Reinhardt; A H Tulusan
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 2.  Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options.

Authors:  Francesco Cosentino; Luigi Carlo Turco; Stefano Cianci; Francesco Fanfani; Anna Fagotti; Salvatore Gueli Alletti; Giuseppe Vizzielli; Salvatore Giovanni Vitale; Antonio Simone Laganà; Francesco Padula; Claudio Coco; Salvatore Pisconti; Giovanni Scambia
Journal:  J Prenat Med       Date:  2016 Jan-Jun

3.  Intraoperative consultation of ovarian neoplasms.

Authors:  C O Spann; J E Kennedy; E Musoke
Journal:  J Natl Med Assoc       Date:  1994-02       Impact factor: 1.798

4.  Pregnancies following conservative treatment of malignant ovarian tumors.

Authors:  K Shiromizu; T Kawana; M Sugase; K Takizawa; K Kawagoe; R Izumi; M Mizuno
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

5.  DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions.

Authors:  B C Padberg; H E Stegner; S von Sengbusch; H Arps; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 6.  Borderline ovarian tumors: a review of treatment.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

Review 7.  Fertility sparing treatment in borderline ovarian tumours.

Authors:  Rosa Maria Alvarez; Daniel Vazquez-Vicente
Journal:  Ecancermedicalscience       Date:  2015-02-03

8.  Borderline epithelial tumors of the ovary: Experience of 55 patients.

Authors:  Vera Loizzi; Luigi Selvaggi; Luca Leone; Donatella Latorre; Doriana Scardigno; Francescapaola Magazzino; Gennaro Cormio
Journal:  Oncol Lett       Date:  2014-12-02       Impact factor: 2.967

9.  Borderline tumors of the ovary: A clinicopathological study.

Authors:  Samia Yasmeen; Abdul Hannan; Fareeha Sheikh; Amir Ali Syed; Neelam Siddiqui
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

10.  Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Authors:  K Nakayama; Y Takebayashi; K Hata; R Fujiwaki; K Iida; M Fukumoto; K Miyazaki
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.